Day: September 9, 2024

LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL, Director of ALS, Center of Excellence.The presentation details are as follows:  Paper Number: 302  Paper Status: Accepted as Poster  Title: COMBAT-ALS...

NEW ALBANY, Ohio, Sept. 09, 2024 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI) announced today that James Ray, President and Chief Executive Officer and Andy Cheung, Executive Vice President and Chief Financial Officer, will meet with investors registered at the Barrington Research Virtual Fall Investment Conference on September 12, 2024.  A link to the presentation materials to be used in the meetings will be accessible through the investor section of the Company’s website at cvgrp.com.  For further information, please contact CVGI@alpha-ir.com About CVG At CVG, we deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com. Investor Relations...

TORONTO, Sept. 09, 2024 (GLOBE NEWSWIRE) — Abaxx Technologies Inc., (CBOE: ABXX) (OTCQX: ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announces that it has filed an early warning report in respect of MineHub Technologies Inc. (“MineHub”). On September 9, 2024, pursuant to a share exchange agreement (“SEA”) between Abaxx and MineHub dated July 31, 2024, Abaxx completed a second tranche closing (the “Second Tranche Closing”) and acquired 4,166,666 common shares of MineHub (the “MineHub Shares”). Immediately prior to the Second Tranche Closing,...

Woodward Appoints Ron Charles as Chief Human Resources OfficerRon Charles joins Woodward as CHROFORT COLLINS, Colo., Sept. 09, 2024 (GLOBE NEWSWIRE) — Woodward (NASDAQ: WWD), a leader in aerospace and industrial energy control solutions, today announced the appointment of Ron Charles as its Executive Vice President and Chief Human Resources Officer, effective September 9. In this role, he will lead the company’s overall human resources function, including organizational capability, member experience, talent management, total rewards, and diversity, inclusion and belonging, as well as communications and brand. He will be instrumental in advancing Woodward’s efforts to build its talent powerhouse and create a great place to work. As an Executive Vice President and member of the Woodward Executive Leadership Team, Charles...

DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will deliver an in-person presentation at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. Details are as follows: H.C. Wainwright 26th Annual Global Investment ConferenceDate: September 10, 2024Time: 9am ETLocation: Holmes II, Lotte New York Palace HotelWebcast: click here   The webcast will also be archived on Aprea’s corporate website. Management are also available for one-on-one meetings with institutional investors. To request a meeting, please contact...

TORONTO, Sept. 09, 2024 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) will release the strategic plan for its US molybdenum operations, including results from the Thompson Creek feasibility study and Langeloth Metallurgical Facility commercial optimization plan, after the market closes on Thursday, September 12, 2024. The Company will host a conference call and webcast to discuss the release on Friday, September 13, 2024, at 9:00 a.m. Eastern Time. Details for the conference call and webcast are included below. WebcastParticipants can access the webcast at the following link. An archive of the webcast will be available for until end of day December 13, 2024.Conference CallParticipants can register for the conference call at the following registration link. Upon registering, you...

Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy WCLC presentation also reviews data on overall survival, progression-free survival and response rate among patients who added chemotherapy to Libtayo following disease progression TARRYTOWN, N.Y., Sept. 09, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced five-year results from the final pre-specified overall survival (OS) analysis of the Phase 3 EMPOWER-Lung 1 trial, which evaluated Libtayo® (cemiplimab) monotherapy versus chemotherapy as a first-line treatment for adults with advanced non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. The late-breaking...

CINCINNATI, Sept. 09, 2024 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the “Operating Partnership”), has priced a public offering of $350 million aggregate principal amount of 4.950% senior unsecured notes due 2035 (the “Notes”). The Notes were priced at 98.458% of the principal amount and will mature on January 15, 2035. The offering is expected to settle on September 12, 2024, subject to the satisfaction of customary closing conditions. The notes will be fully and unconditionally guaranteed by PECO. The Operating Partnership intends to use the net proceeds...

If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh 30 kg (66 lbs.) or greater SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) —  ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the submission of a supplemental New Drug Application (sNDA) for neffy® 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who weigh 15 to 30 kg (33-66 lbs.). Pharmacokinetic...